AOD-9604 (2mg)
AOD-9604 dosing protocols utilize this synthetic 16-amino acid fragment (Tyr‑hGH 177–191) to support lipolysis and inhibit lipogenesis without increasing IGF‑1 or causing insulin resistance. Clinical trials showed a safety profile similar to placebo in obese adults. This protocol outlines a once-daily subcutaneous approach with the 2 mg vial.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full AOD-9604 encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
AOD‑9604 is a modified C‑terminal fragment of hGH that retains its lipolysis domain without growth-related effects. It binds to adipose tissue, activating the breakdown of stored fat while blocking new storage. Chronic administration upregulates β3‑adrenergic receptors. It does not significantly increase IGF‑1 or worsen glucose tolerance.
Quick Start
- Reconstitution: Add 3.0 mL bacteriostatic water → ~0.667 mg/mL (667 mcg/mL) concentration.
- Typical daily range: 300–500 mcg once daily (gradual titration).
- Storage: Lyophilized: −20 °C; after reconstitution, refrigerate at 2–8 °C; avoid freeze-thaw cycles.
Typical / Titrated Approach (3 mL = ~0.667 mg/mL)
Route: Subcutaneously | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 300 mcg | 45 Units (0.45 mL) |
| Weeks 5–12 | 500 mcg | 75 Units (0.75 mL) |
Studies report administration once daily subcutaneously (usually morning on an empty stomach). Alternate injection sites (abdomen, thighs, arms).
Related compounds
Reconstitution Steps
- Draw 3.0 mL of bacteriostatic water.
- Inject slowly down the side of the vial; avoid frothing.
- Gently swirl until dissolved (do not shake vigorously).
- Label and refrigerate at 2–8 °C, protected from light.
Protocol Overview
- Goal: Support fat mass reduction and enhance fat oxidation.
- Schedule: Daily subcutaneous injections for 8–12 weeks (extendable to 16).
- Storage: Lyophilized frozen; reconstituted refrigerated.
Dosing Protocol
- Initiation: 300 mcg daily for Weeks 1–4.
- Target: 500 mcg daily from Week 5.
- Frequency: Once daily (subcutaneously).
- Cycle Duration: 8–12 weeks; optional extension to 16.
- Timing: Morning (fasted); rotate sites.
- Break between cycles: After the cycle (8–12 weeks), a 4–6 week break is recommended. AOD-9604 is an HGH fragment — a break prevents tolerance to its lipolytic action.
Washout & Cycle Restart
When can I restart?
After the cycle (8–12 weeks), a 4–6 week break is recommended. AOD-9604 is an HGH fragment — a break prevents tolerance to its lipolytic action.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: Store at −20 °C; stable for 1+ year.
- Reconstituted: Refrigerate at 2–8 °C; use within 3–4 weeks; avoid freeze-thaw.
- Allow to reach room temperature before opening.
Important Notes
- Each 2 mg vial provides ~4 days at 500 mcg/day or ~6–7 days at 300 mcg/day.
Potential Benefits & Side Effects
Potential Benefits:
- Supports reduction in fat mass (~2.6 kg vs 0.8 kg placebo over 12 weeks).
- Preferential loss of abdominal fat.
- Does not increase IGF‑1; safety profile similar to placebo.
- Potential cartilage repair and bone health benefits (preclinical).
- Generally well-tolerated; mild injection site reactions.
Potential Side Effects:
- Injection site reactions (10–30%): redness, swelling.
- Headache (1–10%, comparable to placebo).
- Nausea (1–10%, rare).
- Fatigue or flu-like symptoms (rare).
- Dizziness (<1%).
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Failed clinical trials — questionable efficacy
The Phase III obesity trial did not meet primary endpoint. Long-term safety as injectable has not been documented (GRAS only for oral use).
📄 Metabolic Pharmaceuticals (Clinical Trial Data)References
- Journal of Endocrinology and Metabolism (2014) — Safety and metabolism of AOD9604
View Source - Journal of Endocrinology and Metabolism (2013) — Safety and tolerability of AOD9604 in humans
View Source - FDA PCAC (2024) — Memorandum on AOD‑9604 bulk drug substance
View Source - Endocrinology (OUP) — Effects of hGH and AOD9604 on lipid metabolism
View Source - Gastroenterology — AOD‑9604 clinical results in an RCT
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
GRAS (oral) — Not approved as an injectable
FDA GRAS (oral only)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →